Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Biotechs Hit By Price Cuts Write Down $84.8m

Executive Summary

From BeiGene and Innovent to Zai Lab, companies have written down amounts equivalent to 44% of their combined product revenues in the fourth quarter of 2021 to compensate distributors after reimbursement prices for oncology drugs were slashed sharply by the government related to inclusion in a national reimbursement list.

You may also be interested in...



Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m

Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing

Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel